Wall Street analysts forecast that Insulet (PODD) will report quarterly earnings of $0.81 per share in its upcoming release, pointing to a year-over-year increase of 11%. It is anticipated that revenues will amount to $541.33 million, exhibiting an increase of 22.6% compared to the year-ago quarter.

The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

With that in mind, let's delve into the average projections of some Insulet metrics that are commonly tracked and projected by analysts on Wall Street.

The collective assessment of analysts points to an estimated 'Revenue- Total Omnipod' of $534.28 million. The estimate indicates a change of +23.4% from the prior-year quarter.

Analysts predict that the 'Revenue- Drug Delivery' will reach $7.37 million. The estimate suggests a change of -15.3% year over year.

Analysts expect 'Revenue- International Omnipod' to come in at $144.78 million. The estimate indicates a year-over-year change of +25.6%.

The average prediction of analysts places 'Revenue- U.S. Omnipod' at $389.50 million. The estimate indicates a change of +22.6% from the prior-year quarter.

View all Key Company Metrics for Insulet here>>>

Over the past month, shares of Insulet have returned +4.8% versus the Zacks S&P 500 composite's +0.4% change. Currently, PODD carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Insulet Corporation (PODD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research